E11.42

Type 2 diabetes mellitus with diabetic polyneuropathy

Type 2 diabetes mellitus with diabetic polyneuropathy is a chronic clinical manifestation where long-term hyperglycemia leads to progressive damage of the peripheral nerves. This condition typically presents as distal symmetric polyneuropathy (DSPN), a microvascular complication of diabetes. The pathophysiology involves metabolic and vascular factors, including the activation of the polyol pathway, increased oxidative stress, and the formation of advanced glycation end-products (AGEs), which lead to nerve ischemia and axonal degeneration. It often starts in the longest nerves (the feet) and progresses proximally in a 'stocking-glove' distribution. Management focuses on rigorous glycemic control, lifestyle modifications, and symptomatic treatment of neuropathic pain.

Clinical Symptoms

Numbness or reduced ability to feel pain or temperature changes
Tingling or burning sensations (paresthesia)
Sharp, stabbing pains or cramps
Increased sensitivity to touch (allodynia)
Muscle weakness and loss of reflexes
Loss of balance and coordination (proprioceptive loss)
Foot problems, such as ulcers, infections, and bone or joint pain (Charcot joint)
Nighttime worsening of pain
Loss of vibratory sense

Common Causes

Chronic hyperglycemia (prolonged high blood sugar levels)
Metabolic factors including high triglycerides and low HDL cholesterol
Microvascular damage to the vasa nervorum (blood vessels supplying the nerves)
Oxidative stress leading to nerve cell apoptosis
Advanced glycation end-products (AGEs) damaging nerve structure
Genetic predisposition to neuropathy
Long duration of Type 2 diabetes
Lifestyle factors including smoking and excessive alcohol consumption

Documentation & Coding Tips

Establish causal linkage using specific terminology to ensure proper code assignment.

Example: Patient with a 10-year history of Type 2 diabetes mellitus presenting with distal symmetric polyneuropathy manifested by bilateral stocking-distribution paresthesia. The neuropathy is documented as a direct complication of the patients poorly controlled hyperglycemia (HbA1c 8.4 percent). Billing Focus: Direct linkage between diabetes and the specific manifestation (polyneuropathy) supports E11.42. Risk Adjustment: Triggers HCC 18 (Diabetes with Chronic Complications), reflecting higher complexity and resource utilization.

Billing Focus: Documentation must use terms like with, due to, or associated with to link the neuropathy to the diabetes.

Differentiate between polyneuropathy and mononeuropathy or autonomic neuropathy for high specificity.

Example: Evaluation of Type 2 diabetes mellitus with diabetic polyneuropathy. Patient denies focal weakness or localized nerve entrapment but reports diffuse, bilateral numbness in the lower extremities. Examination confirms loss of sensation in a symmetric distribution. Billing Focus: Distinguishes E11.42 from E11.41 (mononeuropathy) or E11.43 (autonomic neuropathy). Risk Adjustment: Polyneuropathy indicates a systemic microvascular complication impacting the Risk Adjustment Factor score.

Billing Focus: Specific description of the neuropathy type (polyneuropathy vs. mononeuropathy).

Document objective clinical findings from sensory examinations.

Example: Type 2 diabetes mellitus with diabetic polyneuropathy. On physical exam, the patient has 2/10 monofilament sensation at the bilateral first metatarsal heads and absent vibratory sensation at the medial malleoli. Achilles reflexes are 0/4 bilaterally. Billing Focus: Objective evidence supports the medical necessity of the diagnosis code and subsequent neurological testing. Risk Adjustment: Provides clinical validation for the diagnosis in the event of a Risk Adjustment Data Validation audit.

Billing Focus: Physical exam findings (monofilament, tuning fork) justify the polyneuropathy diagnosis.

Incorporate the management plan for neuropathic pain and glycemic control.

Example: Managing Type 2 diabetes mellitus with diabetic polyneuropathy. Current symptoms of burning nocturnal pain are inadequately controlled on Gabapentin 300mg TID; will increase to 600mg TID and optimize basal insulin to target HbA1c below 7.0 percent. Billing Focus: Demonstrates active management of the complication, supporting the complexity of the visit. Risk Adjustment: Reflects the ongoing status of the chronic condition as required by the MEAT (Monitor, Evaluate, Assess, Treat) criteria.

Billing Focus: Documentation of pharmacotherapy and titration supports higher-level E/M coding.

Verify the presence of concurrent diabetic complications like foot ulcers or peripheral vascular disease.

Example: Type 2 diabetes mellitus with diabetic polyneuropathy. Patient has significant loss of protective sensation (LOPS). Inspection of feet shows no current ulceration, but bilateral callous formation is noted over the metatarsal heads. Referred to podiatry for preventative care. Billing Focus: Polyneuropathy often co-exists with other E11. series codes; multiple codes may be needed if multiple complications exist. Risk Adjustment: Polyneuropathy is a key predictor of future high-cost events like amputations.

Billing Focus: Identification of Loss of Protective Sensation (LOPS) supports specific preventative CPT codes.

Relevant CPT Codes

99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making. When using time for code selection, 30-39 minutes of total time is spent on the date of the encounter.
Patients with polyneuropathy usually require moderate MDM due to the management of chronic complications and prescription drug management.
99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a low level of medical decision making. When using time for code selection, 20-29 minutes of total time is spent on the date of the encounter.
Used when the neuropathy is stable and no major changes are made to the treatment plan.
95910 - Nerve conduction studies; 7-8 studies
Used by specialists to objectively quantify the severity of the polyneuropathy.
95886 - Muscle testing, manual (separate procedure) with report; complete bilateral study of muscles in 4 extremities
Assesses the motor component of the polyneuropathy to rule out advanced muscle wasting.
11721 - Debridement of nail(s) by any method(s); 6 or more
Necessary for patients with polyneuropathy who cannot safely perform their own foot care due to loss of sensation.
G0245 - Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS)
Directly evaluates the severity of polyneuropathy for Medicare preventative foot care benefits.
99204 - Office or other outpatient visit for the evaluation and management of a new patient, which requires a moderate level of medical decision making. When using time for code selection, 45-59 minutes of total time is spent on the date of the encounter.
New diabetic patients with complications often require a moderate level of complexity to establish a care plan.
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making. When using time for code selection, 40-54 minutes of total time is spent on the date of the encounter.
Appropriate if the polyneuropathy is progressing rapidly or associated with other acute medical concerns.
99203 - Office or other outpatient visit for the evaluation and management of a new patient, which requires a low level of medical decision making. When using time for code selection, 30-44 minutes of total time is spent on the date of the encounter.
Used for new patients with straightforward, stable polyneuropathy and few other comorbidities.
97597 - Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with open wound edge and devitalized tissue) for the first 20 sq cm or less
Neuropathy leads to ulcers that require specialized debridement techniques.